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Abstract 
Background: Although the clinical outcome of patients with diffuse large B cell lymphoma (DLBCL) has been 
improved by the addition of rituximab to standard chemotherapy, almost one-third fails or relapses after first line 
treatment. The presence of monoclonal gammopathy (MG) is a known adverse prognostic factor for DLBCL. Because 
this subset of patients does not benefit from R-CHOP, new therapeutic options are required. Herein, we report the first 
case of extranodal DBCL of the lung with a concomitant MG who achieved a long lasting complete remission with 
lenalidomide.
Case presentation: The 73-year-old male patient presented with lateral cervical lymphadenopathy, B symptoms, lac-
tate dehydrogenase and beta2-microglobulin elevation. Computed tomography (CT) showed mediastinal lymphad-
enopathy and bilateral lung involvement. Biopsy of both disease locations revealed the presence of DLBCL. Successive 
bone marrow trephine biopsy proved the presence of concordant DLBCL involvement. At the time of diagnosis, a MG 
was present as well. The patient did not respond to the standard treatments, and subsequently underwent lenalido-
mide 25 mg/m2 days 1–21 q28 plus dexamethasone 40 mg days 1–4, 9–12 e 17–20. This therapeutic regimen was 
efficacious and safe as salvage therapy in extranodal DBCL with a MG. Furthermore, we observed a close association 
between DLBCL response to therapy and MG levels, suggesting that the amount of M-protein might be a surrogate 
marker of disease response.
Conclusion: Although DLBCL associated with MG does not respond properly to the standard treatments, it is 
highly sensitive to lenalidomide, which is why we endorse its role as treatment of choice in this subset of patients. 
In addition, MG levels appear to correlate with tumor burden, suggesting that it might be a useful marker of disease 
response. Prospective trials to validate these observations are warranted.
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Background
Diffuse large B-cell lymphoma (DLBCL) is the most com-
mon B-cell non-Hodgkin lymphoma (NHL), accounting 
for about 30 % of all new diagnoses [1]. Despite its typical 
morphology, it is a very heterogeneous disease consisting 
of many subtypes. Gene expression profiling (GEP) stud-
ies have identified three main DLBCL subgroups based 
on the cell of origin: germinal center B-cell (GCB), acti-
vated B-cell (ABC) and unclassified DLBCL being mostly 
represented by primary mediastinal B-cell lymphoma 
(PMBCL) [2, 3]. These three subtypes have distinct onco-
genic driver pathways resulting in a different prognosis 
[4, 5]. In particular, ABC DLBCL patients have shown 
a worse survival than GCB DLBCL when treated with 
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rituximab, cyclophosphamide, vincristine, doxorubicin 
and prednisone (R-CHOP) [6]. Another clinical parame-
ter reflecting the heterogeneity of this disease is the pres-
ence of monoclonal gammopathy (MG) in some patients 
[7]. DLBCL with MG often shows an immunoblastic 
differentiation, however, due to its morphologic resem-
blance with plamosmobastic lymphoma (PBL), diagnosis 
can be controversial. Nevertheless, the immunopheno-
type of these diseases is different: DLBCL with MG usu-
ally express the pan-B-cell antigens [8] while PBL has a 
characteristic immunophenotypic pattern with cluster of 
differentiation (CD) 20 and CD 79a negativity in combi-
nation with markers of post germinal center B-cell and 
plasma cell, such as MUM1+, IgG+, CD 138+, CD 38+ 
[9, 10]. Furthermore, most of PBL develop in the setting 
of viral infection and/or immunodeficiency. In addition, a 
rare variant of PBL is characterized by having a transloca-
tion of ALK to the clathrin gene on chromosome 17 [11]. 
Even multiple myeloma (MM) with plasmobastic features 
present morphological similarities to DLBCL with MG. 
However, its immunophenotype resembles PBL [12–14]. 
Moreover, DLBCL with MG differ from MM with plas-
mobastic features by the absence of bone involvement 
with radiographically evident lytic lesions [15].
Usually, patients affected by DLBCL with MG present 
with advanced stage disease, involvement of extranodal 
sites and high IPI-score [16]. Clinical data suggest that 
DLBCL with MG has a very aggressive clinical course, 
not adequately responding to standard treatments, which 
is why alternative approaches are needed. Lenalidomide, 
an oral immunomodulatory drug (IMiDs) with multiple 
mechanisms of action, including direct antitumor and 
immunomodulatory effects [17], has demonstrated to be 
active as single agent in NHL [18] with a higher response 
rate in non-GCB with respect to GCB patients (55 vs 9 %, 
respectively) [19]. Nevertheless, lenalidomide represents 
the cornerstone of MM management, providing rapid and 
sustained disease control in relapsed/refractory [20, 21] as 
well as in newly diagnosed patients [22]. Based on its dual 
efficacy on lymphoma and on myeloma cells, lenalido-
mide might have a significant role in DLBCL with MG.
Herein, we present the first case of extranodal DBCL 
of the lung associated with a MG resistant to standard 
therapies but highly responsive to lenalidomide. Further-
more, we observed a close association between DLBCL 
response to therapy and MG serum levels, suggesting 
that in this specific situation the dosage of the MG might 
be a valid marker of disease response.
Case presentation
In August 2011, a 73  year-old man presented with lat-
eral cervical lymphadenopathy, B symptoms and lactate 
dehydrogenase (LDH) and beta2-microglobulin (B2  M) 
elevation (890 U/L, upper normal 460 and 3176 ng/mL, 
upper normal 2150, respectively). Computed tomogra-
phy (CT) revealed mediastinal lymphadenopathy and 
bilateral lung involvement. Histological examination of a 
lymph node and lung biopsies detected the presence of 
a DLBCL with an intermediate-high proliferation index 
(55  % Ki-67 positive cells) without plasmoblastic differ-
entiation. In immunohistochemistry, the neoplastic tis-
sue was CD 20+, CD 19+, CD 79 alfa+, CD 10+, CD 3−, 
CD 5−, CD 23+, CD 38−, CD138−, BCL2−, BCL6+, 
MUM1+, suggesting a non-GCB origin [23], and sug-
gestive for IgG expression (Fig.  1). Bone marrow tre-
phine biopsy proved the presence of concordant DLBCL 
involvement. The IPI score was high due to four risk fac-
tors (stage IV, age >60, elevated LDH and >1 extranodal 
site). At the time of diagnosis, a monoclonal gammopa-
thy was accidentally discovered. The M-gradient was of 
immunoglobulin (Ig) G k-type, with a serum concentra-
tion of 22.5  g/dL. Serum λ free light chains (FLC), the 
same subtype as expressed by the neoplastic cells, were 
elevated (410.3  mg/l; range 5.5–355.2) resulting in an 
abnormal κ/λ FLC ratio. All the other Ig levels were nor-
mal (IgA 3.32—normal range 0.82–4.76 g/dL, IgM 1.84—
normal range 0.30–2.27). The Bence-Jones proteinuria 
was absent. The concomitant presence of a multiple mye-
loma was excluded since the bone marrow plasmacytosis 
was less than 5 % and the patient had no end-organ dam-
age according to the CRAB criteria [24]. Since the patient 
was in a good clinical condition (performance status of 
1), he underwent R-CHOP. Due to stable disease assessed 
by CT scan after the fourth cycle treatment was discon-
tinued. At this time the MG remained stable (Fig. 2). Six 
months later the patient suffered a histological-proven 
progression in the lung. Due to a poor performance sta-
tus (PS 2) at the time of relapse and his ineligibility to 
ASCT, the patient underwent bendamustine 100 mg/m2 
days 1–2 q28 plus rituximab 375 mg/m2 every 28 days for 
four cycles. Disease restaging after treatment completion 
revealed progressive disease (PD) (Fig.  3) as well as an 
increase of the MG (Fig. 2). Due to the lack of other treat-
ment options, he finally underwent lenalidomide 25 mg/
m2 days 1–21 q28 thereafter. Dexamethasone 40 mg days 
1–4, 9–12 e 17–20 for the first four cycles and only days 
1–4 was added as well. This because dexamethasone has 
demonstrated activity as single agent in reducing para-
proteinemia and improving quality of life [25, 26]. More-
over, it synergistically inhibits tumor growth and induces 
apoptosis when combined with lenalidomine [27].
Hematologic toxicity was limited to reversible grade 
two neutropenia and thrombocytopenia after the sixth 
cycle. Except for fatigue grade two, no extra-hematologic 
toxicities were observed. Two months after treatment 
start, the patient’s general conditions improved and after 
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5 months he achieved a complete remission (CR) (Fig. 3). 
For the first time paraprotein was no longer detectable 
and immunofixation (IF) was negative as well (Fig.  2). 
Overall, the patient underwent 15 cycles of lenalidomide 
until he suffered relapse leading to death. Interestingly, 
the reappearance of a monoclonal IgG and of FLC k/l 
abnormal ratio preceded relapse (Fig. 2).
Herein, we report the case of a patient with DLBCL of 
the lung associated with the presence of a sieric MG of 
IgG λ type. Despite the histologic morphology not being 
Fig. 1 Diffuse large B-cell lymphoma (DLBCL) in lymph node biopsy. Immunohistochemistry revealed IgG staining in the cytoplasm of some neo-
plastic cells (IgG stain; original magnification, ×200). Absence of CD38 expression in neoplastic cells and a positive staining in intermingled plasma 
cells (original magnification, ×400). Absence of CD138 stain in neoplastic cells (original magnification, ×400)
Fig. 2 Trend of γ-globulin dosage during the disease course
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compatible with a plasmablastic differentiation, the levels 
of MG following lymphoma response and the absence of 
multiple myeloma features suggest that the paraprotein 
was produced by the lymphoma cells. Moreover, neoplas-
tic cells represented with a λ light chain restriction the 
same subtype of light chain as the aberrant MG. As previ-
ously reported by others, MG was associated with a non-
GCB subtype [28]. This could probably be explained by 
the fact that ABC DLBCL develops from post-germinal 
center B-cells and is associated with an up-regulation of 
Blimp-1, which is a master regulator of plasma cell differ-
entiation [29]. Consistent with previous reports [9, 28], 
the presence of MG was associated with advanced stage, 
involvement of extranodal sites, elevated LDH and high 
IPI score. Despite this usually unfavorable risk profile at 
diagnosis, data regarding the outcome of such patients 
are still conflicting. Maurer et al. [30] showed that a mon-
oclonal elevation of FLC ratio was only moderately asso-
ciated with DLBCL outcome, while more recent analyses 
have observed a poor outcome in DLBCL with parapro-
teinemia [28, 31], especially in the ABC subtype [7].
As also observed by others, the benefit from R-CHOP 
in patients with DLBCL with a serum MG is very limited 
[7, 16] and new therapeutic options are required. Lena-
lidomide has demonstrated to be highly active in non-
GCB [29] as well as in MM [22]. Recent insights into the 
biology of IMiDs have identified cereblon, a substrate-
recognition component of an ubiquitin ligase [32], as a 
crucial molecule for the immunomodulatory and anti-
proliferative activities of lenalidomide [33, 34]. Lena-
lidomide-bound cereblon acquires the ability to target 
the proteosomal degradation of two B-cell transcription 
factors, IKZF1 and IKZF3, an essential step in the anti-
myeloma effect [35]. In addition, lenalidomide induces 
the cereblon-mediated down-regulation of IFR4 leading 
to inhibition of the B-cell receptor-NF-kB signaling path-
way [34], which is aberrant in ABC DLBCL [2]. Despite 
breakthrough studies that identified cereblon as a critical 
lenalidomide target [32, 33], there are challenges in its 
use as a biomarker. In particular, no correlation between 
cereblon gene expression or protein level to sensitivity or 
to intrinsic resistance to lenalidomide treatment has been 
observed [36, 37]. Therefore, the clinical value of cer-
eblon expression as a predictive or prognostic biomarker 
is still questionable.
In our case, despite inefficacy of R-CHOP and R-ben-
damustine, lenalidomide induced a complete response 
with the disappearance of paraproteinemia. This striking 
efficacy might be related to its dual activity on lymphoma 
and on plasma cells, allowing to overcome the adverse 
effect connected to ABC DLBC and MG. Moreover, the 
favorable toxicity profile of lenalidomide translates into 
a high feasibility since ABC DLBC with MG are more 
common among old age patients [7]. Interestingly, we 
observed a direct correlation between DLBCL response 
to treatment and MG serum levels, suggesting that the 
aberrant proteins were produced by the neoplastic cells. 
Consequently, the monoclonal component might be used 
as a marker of disease in such cases.
Conclusions
In conclusion, these data suggest that DLBCL associated 
with monoclonal gammopathy does not respond properly 
to the standard treatments while it could be highly sensi-
tive to lenalidomide. The IMID was able to overcome the 
negative impact of MG and ABC DLBCL on response, 
which is why lenalidomide might be the treatment of 
choice for this subset of patients. In addition, MG levels 
Fig. 3 Computed tomography (CT) of the torax. a Pathological tissue with elongated morphology of maximum diameter of 6 cm. b Almost com-
plete disappearance of the pathological mass previously observed
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appear to correlate with tumor burden, suggesting that it 
might be a useful marker of disease response. Prospective 
trials to validate these observations are warranted.
Consent
Written informed consent was obtained from the patient 
for the publication of this report and any accompanying 
images.
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